

# Plasma Protein Products Transition

January 2018

## NEWS

This newsletter is a follow-up to the December 2017 edition and is intended for a general audience including health-care professionals and patients.

### Immune globulin

Immune globulin (IG) products distributed by Canadian Blood Services are manufactured from either a) plasma supplied by Canadian Blood Services or b) plasma from non-Canadian Blood Services' sources, referred to as commercial product\*.

#### Total IG target percentages

Shire	Grifols	Grifols	CSL
60%	15%	15%	10%
*Gammagard Liquid *Gammagard SD *Cuvitru	*Gamunex	IGIVnex	Privigen

### Albumin 5% 250mL

After transition has been completed, Alburex from CSL will be the primary commercial albumin 5% 250 mL product. Other concentration/volumes will be available from both Grifols and CSL (see table on page 2).

### Transition support

Canadian Blood Services will continue to provide updated information in this newsletter on product ordering, current national inventory levels and other relevant information.

### National inventory

Please see page 3 of this newsletter for an update on impacted products in our inventory. Limited quantities of discontinued products will be available to manage the transition to new products as local inventories become depleted.

### Ordering products

If your order exceeds a one-month supply, please submit it at least one week prior to patient use. Order forms can be found at [www.blood.ca](http://www.blood.ca).



Canadian Blood Services  
it's in you to give

## CHANGES

- **Hizentra 1g and 2g pre-filled syringes** are available at Canadian Blood Services' sites. Hospitals should ensure necessary training has been scheduled or completed prior to ordering product.
- **Cuvitru 1g and 2g vials** have been delivered to Canadian Blood Services and Shire has started to schedule training. Product will be distributed to Canadian Blood Services sites as training is completed. Hospitals should ensure necessary patient training has been scheduled or completed prior to ordering product.

Cuvitru activities	Target start date
Health Care Professionals (HCP) education, training and associated materials received by HCP.	Mid-January, 2018
Patient education and materials received by patients via HCP.	Late January, 2018
OnePath enrollment form distribution and completion.	Mid-January, 2018
OnePath home care patient training for Cuvitru: Training schedules established. Reimbursement/certification forms provided.	Early March, 2018
All sizes of Cuvitru available to hospitals.	Early April, 2018

- There are no updates related to factor concentrates. Canadian Blood Services is on track to receive long acting Adynovate (rFVIII) and Rebinyn (rFIX) in March/April 2018 respectively.
- Patients meeting specific criteria will be able to remain on Eloctate or Alprolix. Processes associated with managing product for these patients are under development.

### CONTACT US

**Day-to-day operations and additional information on products and inventory:** Contact your local Canadian Blood Services site or Jennifer Davis, plasma protein products and services team, [jennifert.davis@blood.ca](mailto:jennifert.davis@blood.ca).

#### New products and product support:

Hizentra CARE 1-888-490-4105  
Shire 1-888-999-0287  
Novo Nordisk 1-800-465-4334

# SUMMARY OF PRODUCT CHANGES

Red (underlined): not continuing

Blue (**bold**): new

Today's product mix		Future product mix	
Product	Size	Product	Size
<b>Intravenous Immune Globulin</b>		<b>Intravenous Immune Globulin</b>	
Gamunex, Grifols	2.5g, 5g, 10g, 20g	Gamunex, Grifols	2.5g, 5g, 10g, 20g
IVIgNex, Grifols	20g	IVIgNex, Grifols	20g
Privigen, CSL Behring	<u>2.5g, 5g</u> , 10g, 20g, <u>40g</u>	Privigen, CSL Behring	10g, 20g
Gammagard Liquid, Shire	5g, 10g	Gammagard Liquid, Shire	<b>2.5g</b> , 5g, 10g, <b>20g, 30g</b>
<u>Panzyga, Octapharma</u>	<u>2.5g, 5g, 10g, 20g, 30g</u>		
<b>Subcutaneous Immune Globulin</b>		<b>Subcutaneous Immune Globulin</b>	
<u>Hizentra, CSL Behring</u>	<u>1g, 2g, 4g, 10g</u>	<b>Cuvitru, Shire</b>	<b>1g, 2g, 4g, 8g</b>
<b>Albumin</b>		<b>Albumin</b>	
Plasbumin, Grifols	5% 50 mL, <u>5% 250 mL</u> , <u>25% 100 mL</u>	Plasbumin, Grifols	5% 50 mL
Albumin, Grifols	25% 100 mL	Albumin, Grifols	25% 100 mL
Alburex, CSL Behring	5% 250 mL, 5% 500 mL, 25% 50 mL, 25% 100 mL	Alburex, CSL Behring	5% 250 mL, 5% 500 mL, 25% 50 mL, 25% 100 mL
<b>Recombinant factor VIII</b>		<b>Recombinant factor VIII</b>	
Xyntha, Pfizer	250 IU, 500 IU, 1000 IU, 2,000 IU, 3000 IU	Xyntha, Pfizer	250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU
Nuwiq, Octapharma	250 IU, 500 IU, 1000 IU, 2000 IU	Nuwiq, Octapharma	250 IU, 500 IU, 1000 IU, 2000 IU
Kovaltry, Bayer	250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU	Kovaltry, Bayer	250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU
<u>Eloctate, Bioverativ (long-acting) *</u>	<u>250 IU, 500 IU, 750 IU, 1000 IU</u> , <u>1500 IU, 2000 IU, 3000 IU</u>	<b>Adynovate, Shire (long-acting)</b>	<b>250 IU, 500 IU, 1000 IU, 2000 IU</b>
<b>Recombinant factor IX</b>		<b>Recombinant factor IX</b>	
Benefix, Pfizer	500 IU, 1000 IU, 2000 IU, 3000 IU	Benefix, Pfizer	500 IU, 1000 IU, 2000 IU, 3000 IU
<u>Alprolix, Bioverativ (long-acting) *</u>	<u>500 IU, 1000 IU, 2000 IU, 3000 IU</u>	<b>Rebinyn, Novo Nordisk (long-acting)</b>	<b>500 IU, 1000 IU, 2000 IU</b>

\*Quantities of product to remain available for special needs cases.

# INVENTORY UPDATE

as of January 2018

<b>CSL Hizentra</b>	<b>Baxalta Cuvitru</b>	<b>Grifols Gamunex</b>	<b>CSL Privigen</b>	<b>Grifols Plasbumin 5% 250 mL</b>	<b>Bioverativ Eloctate</b>	<b>Baxalta Adynovate</b>
Total grams: 100,343 Total vials: 1g vial = 0 2g vial = 2,274 4g vial = 7,159 10g vial = 1,467 1gPFS = 2,299 2gPFS = 25,095	Total grams: 28,810 Total vials: 1g = 3,564 2g = 12,623	Total grams: 334,738 Total vials: 2.5g = 849 5g = 3,877 10g = 4,575 20g = 13,374	Total grams: 93,828 Total vials: 2.5g = 165 5g = 725 10g = 879 20g = 2,194 40g = 928	Total grams: 165,712 Total vials: = 13,257	Total IU: 9,876,984 Total vials: 250 = 1,351 500 = 265 750 = 137 1000 = 850 1500 = 833 2000 = 1,774 3000 = 1,219	Total IU: 0
<i>No further deliveries of 1g and 2g vials. Limited PFS 1g and 2g syringes introduced to manage transition</i>	<i>All sizes will be available in April 2018</i>	<i>All sizes will continue to be available</i>	<i>Phase out of 2.5g will be monitored during the year. Phase out of 40g August 2018</i>	<i>Plasbumin 5% 250 mL last delivery March 2018</i>		<i>Product will be available March 2018</i>

<b>Octapharma Panzyga</b>	<b>Baxalta Gammagard Liquid</b>	<b>Grifols IVIGnex 20g</b>	<b>Grifols Albumin 25% 100 mL</b>	<b>Bioverativ Alprolix</b>	<b>Novo Nordisk Rebinyn</b>
Total grams: 135,868 Total vials: 2.5g = 117 5g = 529 10g = 1,433 20g = 3,941 30g = 1,327	Total grams: 2,850 Total vials: 5g = 427 10g = 37 30g = 40	Total grams: 72,660 Total vials: = 3,633	Total grams: 880,000 Total vials = 35,200	Total IU: 2,367,650 Total vials: 500 = 221 1000 = 219 2000 = 438 3000 = 387	Total IU: 0
	<i>All sizes will be available in March 2018</i>		No further deliveries of Plasbumin 25% 100 mL		<i>Product will be available April 2018</i>